A Randomized Study of Amcenestrant (SAR439859) Plus Palbociclib

Recruiting

18 years - 99 years

All

Phase 3

500 participants needed

1 Location

Brief description of study

The purpose of the study is to evaluate whether SAR439859 (an experimental hormonal treatment), in combination with palbociclib is a better option compared to letrozole (a standard hormonal treatment), in combination with palbociclib, in terms of efficacy and tolerance for treating patients with ER (+), HER2 (-) breast cancer. Eligible patients will be those with patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Cancer, Breast Cancer
Age: 18 years - 99 years
Gender: All

Male or Female Age 18 or older Diagnosis of Breast Cancer

Updated on 04 Aug 2024. Study ID: 849538

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Randomized Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+) HER2 (-) Breast Cancer

Brief description of study

Eligibility of study

Find a site

Interested in the study